Evidence map›Paper›PMID 42613959›Full record

ArticleThe Medical journal of Australia2026

Early-Onset Colorectal Cancer With Liver-Only Metastases: A Retrospective Cohort Study Integrating Prospectively Collected Real-World Clinical and Molecular Data From an Australian National Database (2009-2024) to Guide Treatment Planning.

Savio G Barreto, Christos S Karapetis, Shahid Ullah, Matthew Burge, Susan Caird, Angus Campbell, Azim Jalali, Ross Jennens, Muhammad A Khattak, Belinda Lee and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Medical journal of Australia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Savio G BarretoFlinders Medical Centre, Adelaide, South Australia, Australia.ORCID https://orcid.org/0000-0002-4999-5657
Christos S KarapetisFlinders Health and Medical Research Institute, Flinders University, Adelaide, South Australia, Australia.
Shahid UllahFlinders Health and Medical Research Institute, Flinders University, Adelaide, South Australia, Australia.
Matthew BurgeRoyal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
Susan CairdGold Coast University Hospital, Gold Coast, Queensland, Australia.
Angus CampbellWalter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
Azim JalaliWalter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
Ross JennensEpworth Healthcare, Melbourne, Victoria, Australia.
Muhammad A KhattakFiona Stanley Hospital, Perth, Western Australia, Australia.
Belinda LeeWalter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
Stephanie H LimMacarthur Cancer Therapy Centre, Campbelltown Hospital, Sydney, New South Wales, Australia.
Shehara MendisWalter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
Louise NottRoyal Hobart Hospital, Hobart, Tasmania, Australia.
Timothy J PriceQueen Elizabeth Hospital, Adelaide, South Australia, Australia.
Jeremy D ShapiroCabrini Health, Melbourne, Victoria, Australia.
Jeanne TieWalter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
Javier TorresGoulburn Valley Health, Shepparton, Victoria, Australia.
Colin WilliamsWalter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
Rachel WongEastern Health, Melbourne, Victoria, Australia.
Vanessa WongWalter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
Peter GibbsWalter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo leverage the Treatment of Recurrent and Advanced Colorectal Cancer (TRACC) registry (an Australian cancer database) to explore the ideal timing and sequence of therapies and the factors influencing these decisions in colorectal cancer (CRC) patients with liver-only metastases to inform contemporary decision-making and future trials. STUDY TYPE: Retrospective registry-based cohort study using the TRACC registry. SETTING AND

participantsConsecutive patients with liver-only metastatic CRC enrolled in the TRACC registry.

main outcome measuresTo explore cancer biology, intended treatment at presentation, actual treatment received and the resultant outcomes for early-onset CRC (EOCRC) (≤ 50 years) and late-onset CRC (LOCRC) (> 50 years) patients with liver-only metastases from a real-world perspective.

resultsBetween 14 January 2009 and 2 September 2024, 1691 patients with liver-only metastatic CRC were enrolled in TRACC. These included 276 EOCRC patients (16.3%) and 1415 LOCRC patients (83.7%). In the EOCRC subset, there were more females (48.2% vs. 34.5%, p < 0.001), less comorbidity (Charlson comorbidity index score 0, 90% vs. 59%, p < 0.001), more left-sided primaries (76.1% vs. 65.7%, p < 0.001), more synchronous disease (53.3% vs. 42.1%, p < 0.001) and BRAF V600E mutations (13.9% vs. 8.1%; p = 0.010). Overall, EOCRC patients had a longer median survival compared with LOCRC patients (3.20 vs. 2.38 years, p < 0.001). For the 662 patients (39.1%) undergoing liver resection, median survival was 5.99 years in EOCRC patients and 5.88 years in LOCRC patients. For all patients and for those undergoing resection, respectively, B-Raf proto-oncogene, serine/threonine kinase (BRAF) (hazard ratio, 1.97 [p < 0.001] and hazard ratio, 2.25 [p < 0.001]) and Kirsten rat sarcoma viral oncogene homologue (KRAS) mutations were associated with worse outcomes (hazard ratio, 1.29 [p < 0.001] and hazard ratio, 1.34 [p = 0.003]).

conclusionDifferences in sex distribution, BRAF mutation rates, primary tumour site and overall survival suggest biological differences between EOCRC and LOCRC. Liver resection was associated with improved survival in LOCRC, with the benefits of all therapies varying depending on age, primary tumour site and whether patients presented with synchronous or metachronous liver-only metastases.

Indexed as

Colorectal NeoplasmsLiver NeoplasmsAdultAgedAged, 80 and overAge of OnsetAustraliaDatabases, FactualFemaleHumansMaleMiddle AgedProto-Oncogene MasProto-Oncogene Proteins B-rafRegistriesRetrospective StudiesBRAF protein, humanMAS1 protein, humanProto-Oncogene MasProto-Oncogene Proteins B-rafcancercarcinomachemotherapycolorectal neoplasmsdigestive system neoplasmsliver neoplasmssurgical oncology

Identifiers

PMID42613959
PMCPMC13487442

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.